Safety of tralokinumab in pediatric patients aged 12-17 with moderate-to-severe atopic dermatitis: results from the Phase 3 ECZTRA 6 trial

Authors
Category Primary study
JournalJournal of Clinical and Aesthetic Dermatology
Year 2023
This article has no abstract
Epistemonikos ID: 702988b758e83ce05a6df1b078bbb8b40758abbd
First added on: Feb 15, 2025